James Stevenson, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the impact of a stage IV non-small cell lung cancer (NSCLC) care pathway on frontline and maintenance chemotherapy use.
Ruxolitinib Extended-Release Could Mitigate Risk/Increase Compliance for Patients With MPNs
March 24th 2023In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, provided an in-depth discussion on the complete response letter issued to ruxolitinib extended-release, and why continued evaluation of the agent could be beneficial for patients with MPNs.
Read More
Updates on Recent Advances and Treatments for Hematologic Malignancies
March 22nd 2023In an interview with Targeted Oncology, Guenther Koehne, MD, PhD, provided an overview of The Summit of Americas on Immunotherapies for Hematologic Malignancies and some of the recent and exciting advances being seen in the hematology space.
Read More
Patritumab Deruxtecan Elicits Clinical Activity in Some Patients With Lung and Breast Cancer
March 20th 2023Two studies of patritumab deruxtecan in patients with EGFR-mutated metastatic non–small cell lung cancer and HER3-expressing metastatic breast cancer revealed promising overall response, disease control, progression-free survival rates, and more.
Read More
2 Clarke Drive
Cranbury, NJ 08512